In clinicopathological researches, serum IGF-1 level and tissue expression of IGF-1 decrease in liver diseases, including hepatic steatosis, fibrosis, and cirrhosis; whereas systemic IGF-1 administration can ameliorate liver function and fibrosis29. Here, IGF1 is linked to fatty liver disease.